Hematoporphyrin 血卟啉; Hematoporphyrin IX|cas:14459-29-1|西域试剂

Hematoporphyrin 血卟啉; Hematoporphyrin IX,95.81%

产品编号：Bellancom-B0754| CAS NO：14459-29-1| 分子式：C₃₄H₃₈N₄O₆| 分子量：598.69

Hematoporphyrin (Hematoporphyrin IX) 是血红素结合蛋白亲和色谱底物。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-B0754		￥900.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Hematoporphyrin 血卟啉; Hematoporphyrin IX

产品介绍

Hematoporphyrin (Hematoporphyrin IX) 是一种光敏剂，是血红素结合蛋白亲和色谱底物。当暴露于红光下时，Hematoporphyrin 可以诱导 U87 胶质瘤细胞凋亡，并降低体内肿瘤的生长。

生物活性

Hematoporphyrin (Hematoporphyrin IX), a photosensitizer, is a substrate for affinity chromatography of heme-binding proteins. Hematoporphyrin can induce apoptosis in U87 glioma cells and decrease tumor growth in vivo when exposed to red light.

体外研究

Hematoporphyrin (20-120 nM; 60 min) dose-dependently inhibits cell viability in U87 and U251 glioma cells, with IC₅₀s of 85 and 166 nM, respectively.
Hematoporphyrin (85 nM; 60 min) induces cell apoptosis via induction of ROS in U87 cells.
Hematoporphyrin (85 nM; 60 min) induces morphological changes of U87 cells under the red light, including shrinking, fragmentation.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	U87 and U251 cells
Concentration:	20, 40, 60, 80, 100, 120 nM
Incubation Time:	60 min
Result:	Inhibited cell viability in a dose-dependent manner. Was more effective under the red light than white light.

Apoptosis Analysis

Cell Line:	U87 cells
Concentration:	85 nM
Incubation Time:	60 min
Result:	Induced apoptotic nuclei in U87 cells with low cell density. Induced the ROS and decreased the mitochondrial membrane potential.

体内研究
(In Vivo)

Hematoporphyrin (5-10 mg/kg; i.p. for 2 months) with the irradiation of red light rapidly decreases the tumor size of rats, due to necrosis caused both by direct action of the photoactivated porphyrin on the tumor cells and by secondary effects on blood vessels.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wistar albino rats of both sexes (20 d; 60-80 g) bearing a subcutaneous solid Yoshida hepatoma AH-130
Dosage:	5, 10 mg/kg
Administration:	I.p. daily during the initial 10 days and biweekly for the next 2 months
Result:	No tumor could be palpated a few days after exposure of the rats to light. The skin healed completely and regrowth of the hair occurred. Massive coagulation necrosis of the tumor 24 h after phototreatment (×40).

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wistar albino rats of both sexes (20 d; 60-80 g) bearing a subcutaneous solid Yoshida hepatoma AH-130
Dosage:	5, 10 mg/kg
Administration:	I.p. daily during the initial 10 days and biweekly for the next 2 months
Result:	No tumor could be palpated a few days after exposure of the rats to light. The skin healed completely and regrowth of the hair occurred. Massive coagulation necrosis of the tumor 24 h after phototreatment (×40).

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wistar albino rats of both sexes (20 d; 60-80 g) bearing a subcutaneous solid Yoshida hepatoma AH-130
Dosage:	5, 10 mg/kg
Administration:	I.p. daily during the initial 10 days and biweekly for the next 2 months
Result:	No tumor could be palpated a few days after exposure of the rats to light. The skin healed completely and regrowth of the hair occurred. Massive coagulation necrosis of the tumor 24 h after phototreatment (×40).

性状

Solid

溶解性数据

In Vitro:

DMSO : 150 mg/mL (250.55 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.6703 mL	8.3516 mL	16.7031 mL
5 mM	0.3341 mL	1.6703 mL	3.3406 mL
10 mM	0.1670 mL	0.8352 mL	1.6703 mL

请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (4.18 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.18 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (4.18 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (4.18 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明